Effect of Wnt inhibitors in pancreatic cancer

Anticancer Research

Volumn 34, Issue 10, 2014, Pages 5375-5380

  Wall, Ilona ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Gastrointestinal tumors; Pancreatic cancer; Wnt pathway

Indexed keywords

CICLOPIROXOLAMINE; ETACRYNIC ACID; GRISEOFULVIN; PIROCTONE ETHANOLAMINE; ANTINEOPLASTIC AGENT; CICLOPIROX; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; PYRIDONE DERIVATIVE; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; HUMAN; HUMAN CELL; MTT ASSAY; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; PANCREAS TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG COMBINATIONS; ETHACRYNIC ACID; ETHANOLAMINES; GRISEOFULVIN; HUMANS; PANCREATIC NEOPLASMS; PYRIDONES; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84917710464     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. American Cancer Society. Global Cancer Facts & Figures 2nd Edition. Atlanta: American Cancer Society; 2011.
2. Linke A, Brossart P, Schmidt-Wolf IG, Gonzalez-Carmona MA, Ziske C, Messmer D, Schmitz V and Sauerbruch T: Enhanced inhibition of tumor growth with depletion of CD25 regulatory cells and intratumoral immunization with tumor RNA-pulsed dendritic cells in a C57BL/6 pancreatic tumor model. Pancreas 38(5): 602-604, 2009.
3. Schmidt T, Ziske C, Märten A, Endres S, Tiemann K, Schmitz V, Gorschlüter M, Schneider C, Sauerbruch T and Schmidt-Wolf IG: Intratumoral immunization with tumor RNA pulsed dendritic cells confers antitumor immunitiy in a C57BL/6 pancreatic murine tumor model. Cancer Res 63(24): 8962-8967, 2003.
4. Schneider C, Schmidt T, Ziske C, Tiemann K, Lee KM, Uhlinsky V, Behrens P, Sauerbruch T, Schmidt-Wolf IG, Mühlradt PF, Schmidt J and Märten A: Tumor suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 53(3): 355-361, 2004.
5. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, Kokkinakis DM and Monga SP: Abberant Wnt/β-catenin signaling in pancreatic adenocarcinoma Neoplasia 8(4): 279-289, 2006.
6. Nelson WJ and Nusse R: Convergence of wnt, β-catenin, and cadherin pathways. Science 303(5663): 1483-487, 2004.
7. Willert K and Jones KA: Wnt signaling: is the party in the nucleus? Genes Dev 20(11): 1394-1404, 2006.
8. Kim Y, Thanendrarajan S and Schmidt-Wolf IG: Wnt/β-catenin: a new therapeutic approach to acute myeloid leukemia. Leuk Res Treatment 2011:428960, 2011.
9. Nusse R: Wnt signaling in disease and in development. Cell Res 15(1): 28-32, 2005
10. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R and Ben-Ze'ev: The Cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96(10): 5522-5527, 1999.
11. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 281(5382): 1509-1512, 1998.
12. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps TJ and Carson DA: Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/β-catenin pathway. PLoS ONE 4(12): e8294, 2009.
13. Schmidt M, Sievers E, Endo T, Lu D, Carson D and Schmidt-Wolf IG: Targeting Wnt pathway in lymphoma and myeloma cells. Br J Haematol 144(5): 796-798, 2009.
14. Kim Y, Alpmann P, Blaum-Feder S, Krämer S, Endo T, Lu D, Carson D and Schmidt-Wolf IG: Increased in vivo efficacy of lenalidomide by addition of piroctone olamine. In Vivo 25(1): 99-104, 2011.
15. Kim Y, Alpmann P, Blaum-Feder S, Krämer S., Endo T, Lu D, Carson D and Schmidt-Wolf IG: In vivo efficacy of griseofulvin against multiple myeloma. Leuk Res 35(8): 1070-1073, 2011.
16. Chu EY, Hens J, Andl T, Kairo A, Yamaguchi TP, Brisken C, Glick A, Wysolmerski JJ and Millar SE: Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development 131(19): 4819-4829, 2004.
17. Monga SP, Monga HK, Tan X, Mulé K, Pediaditakis P and Michalopoulus GK: Beta-catenin antisense studies in embyonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 124(1): 202-216, 2003.
18. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S and Haber DA: RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 487(7408): 510-513, 2012.
19. Wells JM, Esni F, Boivin GP, Aronow BJ, Stuart W, Combs C, Sklenka A, Leach SD and Lowy AM: Wnt/β-catenin signaling is required for development of the exocrine pancreas. BMC Developmental Biology 7: 4, 2007.
20. Papadopoulou S and Edlund H: Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function. Diabetes 54(10): 2844-2851, 2005.
21. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW: Activation of β-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275(5307): 1787-1790, 1997.
22. Daa T, Kashima K, Kaku N, Suzuki M and Yokoyama S: Mutations in components of the Wnt signaling pathway in adenoid cystic carcinoma. Mod Pathol 17(12): 1475-1482, 2004.
23. Abraham SC, Klimstra DS, Wilentz RE, Yeo CJ, Conlon K, Brennan M, Cameron JL, Wu TT and Hruban RH: Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor β-catenin mutations. Am J Pathol 160(4): 1361-1369, 2002.
24. Gerdes B, Ramaswamy A, Simon B, Pietsch T, Bastian D, Kersting M, Moll R and Bartsch D: Analysis of β-catenin gene mutations in pancreatic tumors. Digestion 60(6): 544-548, 1999.
25. Pasca di Magliano M, Biankin AV, Heiser PW, Cano DA, Gutierrez PJ, Deramaudt T, Segara D, Dawson AC, Kench JG, Henshall SM, Sutherland RL, Dlugosz A, Rustgi AK and Hebrok M: Common activation of canonical wnt signaling in pancreatic adenocarcinoma. PLoS One 2(11): e1155, 2007.
26. Al-Aynati MM, Radulovich N, Riddell RH and Tsao MS: Epithelial-cadherin and β-catenin expression changes in pancreatic intraepithelial neoplasia. Clinical Cancer Research 10(4): 1235-1240, 2004.
27. Tew KD, Bomber AM and Hoffman SJ: Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 48(13): 3622-3625, 1988.
28. Thanendrarajan S, Kim Y and Schmidt-Wolf IG: Understanding and Targeting the Wnt/β-Catenin Siganling Pathway in Chronic Leukemia. Leukemia Research and Treatment 2011: 329572, 2011.
29. Kim Y, Gast SM, Endo T, Lu D, Carson D and Schmidt-Wolf IG: In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma. Leuk Res 36(5): 598-600, 2012.
30. Aizawa S, Ookawa K, Kudo T, Asano J, Hayakari M and Tsuchida S: Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Science 94(10): 886-893, 2003.
31. Kim Y, Schmidt M, Endo T, Lu D, Carson D and Schmidt-Wolf IG: Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model. In Vivo 25: 887-893, 2011.
32. Kim Y, Reifenberger G, Lu D, Endo T, Carson DA, Gast SM, Meschenmoser K, Nowak M and Schmidt-Wolf IG: Influencing the wnt signaling pathway in multiple myeloma. Anticancer Res 31: 725-730, 2011.
33. Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC and Hube B: Ciclopirox Olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 47(6): 1805-1817, 2003.
34. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J, Antholine WE, Dick JE and Schimmer AD: Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 114(14): 3064-3073, 2009.
35. Zhou H, Shen T, Luo Y, Liu L, Chen W, Xu B, Han X, Pang J, Rivera CA and Huang S: The antitumor activity of the fungicide ciclopirox. Int J Cancer 127(10): 2467-2477, 2010.
36. Schmeel LC, Schmeel FC, Kim Y, Endo T, Lu D and Schmidt-Wolf IGH: Targeting the Wnt/beta-catenin pathway in multiple myeloma. Anticancer Res 33(11): 4719-4726, 2013.
37. Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, Hurren R, Jitkova Y, Gronda M, Isaac M, Joseph B, Subramaniam R, Aman A, Chau A, Hogge DE, Weir SJ, Kasper J, Schimmer AD, Al-Awar R, Wrana JL and Attisano L: Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Cancer Res 71(24): 7628-7639, 2011.
38. Coombs GS, Schmitt AA, Canning CA, Alok A, Low ICC, Banerjee, N, Kaur S, Utomo V, Jones CM, Pervaiz S, Toone EJ and Virshup DM: Modulation of Wnt/β-catenin siganling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene 31(2): 213-225, 2012.